Search results for "Acer"

showing 10 items of 786 documents

Multiple lifestyle factors and depressed mood: a cross-sectional and longitudinal analysis of the UK Biobank (N = 84,860)

2020

Abstract Background There is now evolving data exploring the relationship between depression and various individual lifestyle factors such as diet, physical activity, sleep, alcohol intake, and tobacco smoking. While this data is compelling, there is a paucity of longitudinal research examining how multiple lifestyle factors relate to depressed mood, and how these relations may differ in individuals with major depressive disorder (MDD) and those without a depressive disorder, as ‘healthy controls’ (HC). Methods To this end, we assessed the relationships between 6 key lifestyle factors (measured via self-report) and depressed mood (measured via a relevant item from the Patient Health Questio…

AdultMalemedicine.medical_specialtyAdolescentExacerbationlcsh:Medicinebehavioral disciplines and activitiesYoung Adult03 medical and health sciencesScreen time0302 clinical medicineInternal medicinemental disordersmedicineLifestyle medicineHumansLife StyleLifestyle medicineDepression (differential diagnoses)Biological Specimen BanksDepressive Disorder MajorPhysical activitybusiness.industrylcsh:RGeneral Medicinemedicine.diseaseMental healthUnited KingdomScreen timeDiet030227 psychiatryPatient Health QuestionnaireCross-Sectional StudiesDiet Health Lifestyle medicine Mood disorders Physical activity Screen time Adolescent Adult Biological Specimen Banks Cross-Sectional Studies Depressive Disorder Major Female Humans Male United Kingdom Young Adult Life StyleMood disordersHealthMood disordersMajor depressive disorderFemalebusiness030217 neurology & neurosurgeryResearch Article
researchProduct

Dose-Related Effects of Amisulpride on Five Dimensions of Psychopathology in Patients With Acute Exacerbation of Schizophrenia

2002

The present analysis investigated symptom-specific dose-response relationships of the atypical antipsychotic amisulpride (AMI) in schizophrenic patients. The effects of different AMI doses on five different symptom dimensions of the Brief Psychiatric Rating Scale (BPRS) were analyzed. Results on global efficacy and safety parameters have been previously published. Four AMI doses (100 mg/day [AMI100], 400 mg/day [AMI400], 800 mg/day [AMI800], 1200 mg/day) were compared with 16 mg haloperidol (HAL16) in a multicenter, double-blind, randomized, parallel-group, 4-week trial. A total of 319 patients with acute exacerbation of schizophrenia (DSM-III-R) were included. AMI100 was compared with the …

AdultMalemedicine.medical_specialtyAdolescentExacerbationmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticInternal medicineBrief Psychiatric Rating ScalemedicineHaloperidolHumansPharmacology (medical)AmisulpridePsychiatryAntipsychoticPsychiatric Status Rating ScalesDose-Response Relationship DrugDopamine antagonistMiddle AgedPsychiatry and Mental healthTreatment OutcomeSchizophreniaHaloperidolAnxietyFemaleSchizophrenic PsychologyAmisulprideSulpiridemedicine.symptomPsychologyAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Secondary sclerosing cholangitis after long-term treatment in an intensive care unit: clinical presentation, endoscopic findings, treatment, and foll…

2006

Background and study aims We present ten patients who developed secondary sclerosing cholangitis following long-term treatment in an intensive care unit (ICU) between 1999 and 2004. Patients and methods Ten consecutive patients who had no evidence suggestive of pre-existing hepatobiliary disease were admitted to an ICU because of trauma (n = 5), intracerebral hemorrhage (n = 3), or nonabdominal postsurgical complications (n = 2). All the patients had required treatment with long-term ventilation, catecholamines, total parenteral nutrition, and several antimicrobial agents. Results Cholestasis was first noted within 11 days after the initial insult. Endoscopic retrograde cholangiopancreatogr…

AdultMalemedicine.medical_specialtyCholangitis SclerosingIntrahepatic bile ductslaw.inventionLiver diseaseCholestasislawMedicineHumansAgedIntracerebral hemorrhageCholangiopancreatography Endoscopic RetrogradeEndoscopic retrograde cholangiopancreatographyCholestasismedicine.diagnostic_testbusiness.industryHepatobiliary diseaseGastroenterologyLength of StayMiddle Agedmedicine.diseaseIntensive care unitSurgeryIntensive Care UnitsSecondary sclerosing cholangitisFemalebusinessEndoscopy
researchProduct

Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with sym…

2011

Abstract BACKGROUND Glial fibrillary acidic protein (GFAP) is a biomarker candidate indicative of intracerebral hemorrhage (ICH) in patients with symptoms of acute stroke. GFAP is released rapidly in the presence of expanding intracerebral bleeding, whereas a more gradual release occurs in ischemic stroke. In this study the diagnostic accuracy of plasma GFAP was determined in a prospective multicenter approach. METHODS Within a 1-year recruitment period, patients suspected of having acute (symptom onset <4.5 h before admission) hemispheric stroke were prospectively included into the study in 14 stroke centers in Germany and Switzerland. A blood sample was collected at admission, and …

AdultMalemedicine.medical_specialtyClinical BiochemistryIschemiaBrain IschemiaDiagnosis DifferentialInterquartile rangeInternal medicineGlial Fibrillary Acidic ProteinmedicineHumansIn patientcardiovascular diseasesProspective StudiesProspective cohort studyStrokeAgedCerebral HemorrhageIntracerebral hemorrhageImmunoassayAutoanalysisGlial fibrillary acidic proteinbiologybusiness.industryBiochemistry (medical)Electrochemical TechniquesMiddle Agedmedicine.diseaseSurgeryStrokeAcute DiseaseLuminescent MeasurementsCardiologybiology.proteinBiomarker (medicine)FemalebusinessBiomarkersClinical chemistry
researchProduct

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

2018

Background Mepolizumab has demonstrated favorable safety and efficacy profiles in placebo-controlled trials of 12 months' duration or less; however, long-term data are lacking. Objective We sought to evaluate the long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma (SEA). Methods COLUMBA (Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects, NCT01691859 ) was an open-label extension study in patients with SEA previously enrolled in DREAM (Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma, NCT01000506 ). Patients received 100 mg of subcutaneous mepolizumab every 4 weeks plus standard of care until a protocol-def…

AdultMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsExacerbationInjections Subcutaneous[SDV]Life Sciences [q-bio]ImmunologyEosinophilic asthmaAntibodies Monoclonal HumanizedPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodSurveys and QuestionnairesInternal medicineEosinophiliamedicineHumansImmunology and AllergyIn patientAnti-Asthmatic Agents030212 general & internal medicineAdverse effectRespiratory Tract InfectionsComputingMilieux_MISCELLANEOUSAsthmabusiness.industryMiddle Agedmedicine.diseaseAsthma3. Good healthEosinophils[SDV] Life Sciences [q-bio]Treatment Outcome030228 respiratory systemAsthma Control QuestionnaireBronchitisFemaleInterleukin-5businessMepolizumabmedicine.drug
researchProduct

Measurement of inflammatory mediators of eosinophils and lymphocytes in blood in acute asthma: serum levels of ECP influence the bronchodilator respo…

2002

The aim of this study was to assess the relevance of immunoinflammatory markers on the response to short acting β<sub>2</sub>-agonist in acute asthma exacerbation. Thus, we measured serum eosinophil cationic protein (ECP) levels and sIL-2R at acute exacerbation in 52 adult patients with atopic asthma, and assessed forced expiratory volume in 1 s (FEV<sub>1</sub>) before and after the administration of aerosolized salbutamol. After a cumulative dose of salbutamol causing a 10% improvement in FEV<sub>1</sub> from baseline [CD10, i.e. cumulative doses of salbutamol (800 µg) causing an improvement in FEV<sub>1</sub> from baseline to 10%] the patie…

AdultMalemedicine.medical_specialtyExacerbationAdolescentmedicine.drug_classImmunologyStatistics NonparametricRibonucleasesInternal medicineBronchodilatorForced Expiratory VolumemedicineImmunology and AllergyHumansAlbuterolAsthmaSkin TestsEosinophil cationic proteinCumulative dosebusiness.industryReceptors Interleukin-2General MedicineBlood Proteinsrespiratory systemEosinophilAdrenergic beta-AgonistsEosinophil Granule ProteinsImmunoglobulin EMiddle Agedmedicine.diseaseBlood proteinsAsthmarespiratory tract diseasesBronchodilator AgentsEndocrinologymedicine.anatomical_structureImmunologySalbutamolFemalebusinessmedicine.drugInternational archives of allergy and immunology
researchProduct

Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma.

2019

ARIETTA was a prospective, single-arm, noninterventional, multicenter study in patients with severe asthma.To examine the predictive and prognostic abilities of type 2 biomarkers for severe asthma outcomes.Adult patients with severe asthma receiving daily inhaled corticosteroids (fluticasone propionate ≥500 μg or equivalent) and ≥1 second controller medication were enrolled. Biomarker, clinical, and safety data were collected over 52 weeks. The primary endpoint was the asthma exacerbation rate over 52 weeks in serum periostin-high (≥50 ng/mL at baseline) versus periostin-low subgroups (50 ng/mL). Correlations between biomarker levels (periostin, blood eosinophils, IgE, and fractional exhale…

AdultMalemedicine.medical_specialtyExacerbationRate ratioImmunoglobulin ENitric OxideGastroenterologyFluticasone propionate03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicineClinical endpointImmunology and AllergyHumans030212 general & internal medicineLongitudinal StudiesProspective Studiesbiologybusiness.industryConfidence intervalAsthma3. Good healthEosinophils030228 respiratory systembiology.proteinBiomarker (medicine)FemalebusinessBiomarkersmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

Seasonal variations in the onset and healing rates of venous leg ulcers

2010

Objectives As many vascular pathologies exhibit circannual fluctuation, the aim of this study was to assess the chronobiological features of venous ulcers. Methods Based on a retrospective survey of the case histories of 391 venous ulcer patients, the rates of ulcer onset and healing in each month were analysed statistically; a time series was constructed to evaluate the seasonality. Results There was a significantly higher frequency of ulcer onset during the warmer part of the year (April–October), and onset showed strong seasonality. Healing rates were also unequally and statistically significantly distributed throughout the year: ulcers that appeared or that were treated with specialized…

AdultMalemedicine.medical_specialtyHot TemperatureExacerbationChronic venous insufficiencyModels BiologicalGastroenterologyVaricose UlcerIschemiaRetrospective surveyInternal medicineleg ulcervenous insufficiencymedicineHumansAgedRetrospective StudiesAged 80 and overLegWound Healingbusiness.industryseasonal variationsRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryChemotaxis LeukocyteLeg ulcerFemalePolandSeasonsCardiology and Cardiovascular MedicinebusinessPhlebology: The Journal of Venous Disease
researchProduct

Perinatal cerebral insults alter auditory event-related potentials.

2011

Background: Auditory event-related potentials (AERPs) can be used as indices of neural information processing. Altered AERPs have been reported in children and young adults with frontal lobe infarction. Aim: To test the hypothesis that perinatal brain injury affects cortical auditory processing. Methods: We assessed AERPs at term. 6 and 12 months of age in preterm infants [n = 9. median gestational age (GA) 27.9, range 23.9-30.0 wk], term infants with perinatal intracerebral hemorrhage (ICH) [n = 5, GA 40.3, range 37.4-42.3 wk], and term infants with perinatal asphyxia In [n = 4. GA 39.4. range 37.9-40.3 wk]. Healthy preterm (n = 16) and term infants (n = 22) served as controls. A harmonic …

AdultMalemedicine.medical_specialtyMismatch negativityInfant Newborn DiseasesCentral nervous system disease03 medical and health sciencesYoung Adult0302 clinical medicinePregnancy030225 pediatricsInternal medicinemedicineHumansYoung adultCerebral HemorrhageIntracerebral hemorrhageAsphyxiaAuditory CortexInfant NewbornObstetrics and GynecologyGestational agemedicine.diseasePrognosisSurgeryPerinatal asphyxiaFrontal lobeAcoustic StimulationBrain InjuriesPediatrics Perinatology and Child HealthCardiologyEvoked Potentials AuditoryFemalemedicine.symptomPsychology030217 neurology & neurosurgeryInfant PrematureFollow-Up StudiesEarly human development
researchProduct

Acute Cerebrovascular Disease in the Young

2013

Background and Purpose— Strokes have especially devastating implications if they occur early in life; however, only limited information exists on the characteristics of acute cerebrovascular disease in young adults. Although risk factors and manifestation of atherosclerosis are commonly associated with stroke in the elderly, recent data suggests different causes for stroke in the young. We initiated the prospective, multinational European study Stroke in Young Fabry Patients (sifap) to characterize a cohort of young stroke patients. Methods— Overall, 5023 patients aged 18 to 55 years with the diagnosis of ischemic stroke (3396), hemorrhagic stroke (271), transient ischemic attack (1071) we…

AdultMalemedicine.medical_specialtyPediatricsAdolescentischemiccauseCohort StudiesYoung AdultRisk FactorsmedicineHumansrisk factorsProspective Studiescardiovascular diseasesYoung adultProspective cohort studyStrokeAdvanced and Specialized NursingIntracerebral hemorrhageFabry diseaseCerebral infarctionbusiness.industryAge Factorsimagingyoung strokeMiddle Agedmedicine.diseaseintracerebral hemorrhagestrokeFabry diseaseEuropeStrokeCerebrovascular DisordersNeurologytransient ischemic attackAcute DiseaseCohortPhysical therapyFabry DiseaseFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessCohort studyStroke
researchProduct